Complete if Known Substitute for form 1449A/PTO Application Number 10/581.580 INFORMATION DISCLOSURE Filing Date March 29, 2007 STATEMENT BY APPLICANT First Named Inventor Shyam S. Mohapatra (use as many sheets as necessary) Art Unit 1635 **Examiner Name** Richard A. Schnizer Sheet of Attorney Docket Number 1 2 USF.208TCXC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-7,595,303	09-29-2009	Mohapatra et al.	All
	U2	US-7,655,772	02-02-2010	Mohapatra	All
	U3				
	U4				
	U5				
	U6				
	U7				
	U8				
	U9				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					

Examiner	Date	
Signature	Considered	

"EXAMINET: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Dave the through citation if not in conformance and not considered include copy of this form with east communication to applicant." Applicant's unspire extains designation number opinion in marker opinion in the proprior of USPTO Patent Documents at www.uspic.go.go. or MPEP901.04. "Enter Office that issued the document, by the shortest code (WIPO Standard T3)." For Japanese patient documents, the includance of the year of the region of the Emperor must preced the section number of the patient document to the short fixed of document by the appropriate symbols as the contract of the patient document and the comment of the patient document and the comment of the patient document and the pa

Complete if Known Substitute for form 1449B/PTO Application Number 10/581,580 INFORMATION DISCLOSURE Filing Date March 29, 2007 STATEMENT BY APPLICANT First Named Inventor Shyam S. Mohapatra Group Art Unit 1635 (use as many sheets as necessary) Examiner Name Richard A. Schnizer Sheet of Attorney Docket Number USF.208TCXC1

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	R1	CHHABRA, A. et al. "Silencing of Endogenous IL-10 in Human Dendritic Cells Leads to the Generation of an Improved CTL Response Against Human Melanoma Associated Antigenic Epitope, MART-1" Clin Immunol., March 2008, 126(3):251-259.	
	R2	HEALE, B.S.E. et al. "siRNA target site secondary structure predictions using local stable substructures" Nucleic Acids Research, 2005, 33(3):e30, pp. 1-10.	
	R3	HILL, J.A. et al. "Immune Modulation by Silencing IL-12 Production in Dendritic Cells Using Small Interfering RNA" The Journal of Immunology, 2003, 171:691-696.	
	R4	HU, W-Y, et al. "Inhibition of Retroviral Pathogenesis by RNA Interference" Current Biology, August 6, 2002, 12:1301-1311.	П
	R5	KRETSCHMER-KAZEMI, R. et al. "The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides" Nucleic Acids Research, 2003, 31(15):4417-4424.	
	R6	LI, M. et al. "Immune Modulation and Tolerance Induction by ReIB-Silenced Dendritic Cells through RNA Interference" The Journal of Immunology, 2007, 178:5480-5487.	
	R7	NAIR, M.P.N. et al. "RNAi-directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy" The AAPS Journal, 2005, 7(3):E572-E578.	Ш
	R8	NAWTAISONG, P. et al. "Effective suppression of Dengue fever virus in mosquito cell cultures using retroviral transduction of hammerhead ribozymes targeting the viral genome" Virology Journal, 2009, 6:73, pp. 1-17.	
	R9	QIAN, H. et al. "Silencing CD40 in Dendritic Cells by siRNA" 12 th International Congress of Immunology and 4 th Annual Conference of FOCIS, Montreal, Canada, July 18-23, 2004, 2004, pp. 339-348.	
	R10	SHAO, Y. et al. "Effect of target secondary structure on RNAi efficiency" RNA, 2007, 13:1631-1640.	
	R11	WESTERHOUT, E.M. et al. "A systematic analysis of the effect of target RNA structure on RNA interference" Nucleic Acids Research, 2007, 35(13):4322-4330.	
	R12	YOSHINARI, K. et al. "Effects on RNAi of the tight structure, sequence and position of the targeted region" Nucleic Acids Research, 2004, 32(2):691-699.	
	R13		

Examiner	·	Date
Signature		Considered
*EXAMINER: Initial if	reference considered, whether or not citation is in conformance with MPEP 609.	Draw line through citation if not in conformance and not

"EXAMINEX: Initial if reference consistency whether or not citation is in conformance with MPEP 609. Draw line through citation in of no nonformance and not considered, include copy of this form with next communication to application." Applicant's unique clation designation number (opinion). See Kind Codes of USPTO Patent Documents at <u>www.uspfo.cog</u> or MPEP901.04. Enter Office that issued the document, by the two-letter code (MPEP Standard T3). *For Japanese patent documents, the indication of the year of the reign of the Empireer must preced the searial number of the patent document with Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.